ALMDT Median Technologies

Median Technologies: Liquidity Contract Transfer to Louis Capital Markets

Regulatory News:

Median Technologies (Paris:ALMDT) is announcing that on March 30, 2020, it concluded a new liquidity contract with the Company Louis Capital Markets in accordance with the Amafi charter. The contract will take effect on the morning of May 4, 2020.

This liquidity contract was concluded in accordance with the decision of the Autorité des Marchés Financiers No. 2018-01 of July 2, 2018, applicable since January 1, 2019, establishing liquidity contracts on equity securities as a permitted market practice1.

The End of the Liquidity Contract with AUREL BGC

The companies Median Technologies and AUREL BGC terminated the liquidity contract that was concluded on May 4, 2011. This termination took effect on April 30, 2020 in the evening.

On this date of April 30, 2020 in the evening, the following means appeared in the liquidity account:

  • 4,404 shares,
  • €173,829.64 in cash.

It should be recalled that as of December 31, 2019, the following resources appeared in the liquidity account:

  • 22,458 shares,
  • €141,002.52 in cash.

Regarding the implementation of the new contract concluded with LOUIS CAPITAL MARKETS, the following resources have been allocated to the liquidity account:

  • 4,404 shares transferred from the old liquidity contract,
  • €173,829.64 in cash from the old liquidity contract.

About Median Technologies: Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We leverage the power of Imaging Phenomics to provide insights into novel therapies and treatment strategies. Our unique solutions for medical image analysis and management in oncology trials and iBiopsy® for imaging phenotyping, together with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to therapy. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and precisely bring new treatments to patients in need. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on the Euronext Growth market. ISIN: FR0011049824– ticker: ALMDT. Median is eligible for the French “PEA-PME” investment scheme. For more information: *

______________________

1
The situations or conditions leading to the suspension or termination of the liquidity contract, mentioned in the liquidity contract, are as follows:

Suspension of the contract: - Under the conditions referred to in article 5 of the afore-mentioned AMF decision. Termination of the contract: - At the end of the first 6 months of the first year, the Contract can be terminated at any time by the Issuer, with a 15 day notice under the conditions for closing the liquidity account provided for in the liquidity contract .- By the Animator, with a 15 day notice. - The contract is automatically terminated when the parties cannot, in the situation provided for in article 3.4 (balance of the liquidity account), agree on the action to be taken on the Contract. - By the Facilitator when the Liquidity Provider contract which binds the Moderator to Euronext Paris is terminated.

EN
04/05/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Median Technologies

Median Technologies: 1 director

A director at Median Technologies bought 60,241 shares at 1.660EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

Maria Vara
  • Maria Vara

Median Technologies: EUR23.5m capital raise extends runway into Q4 202...

Median Technologies successfully secured a capital raise via ABSA of EUR23.5m in total gross proceeds, priced at EUR1.66 (at ~18% discount to 20-day VWAP). The offering was oversubscribed, surpassing the initial EUR22m target, with 64% backed by existing shareholders, 2% by a public offering in Fra

Maria Vara
  • Maria Vara

Median Technologies: Launch of EUR22m capital increase to unlock EIB f...

Median Technologies has launched a EUR22m capital increase via a public offering of shares with warrants (ABSA), priced at EUR1.66 (at ~18% discount to 20-day VWAP), with 78% of the deal already secured via existing and new investors. The raise aimed to i) meet the drawing conditions of the Tranche

Maria Vara
  • Maria Vara

Median Technologies: EIB loan signed, tied to equity raise and debt re...

Friday post-market, Median announced the final sign of the EIB loan agreement of EUR37.5m, which has been structured in three tranches (EUR19m, EUR8.5m, EUR10m) and with several key conditions being set to access the first one. These include i) a capital increase of at least EUR16m (including issua

Maria Vara
  • Maria Vara

Median Technologies: CE mark filing keep eyonis on track, US launch be...

Yesterday post-market, Median announced that it has submitted the Class IIb CE marking filing for eyonis LCS, just a month after the FDA 510(k) submission, precisely sticking to the company's timeline guidance. Our confidence in a positive outcome remains high, as both submissions are underpinned b

ResearchPool Subscriptions

Get the most out of your insights

Get in touch